Calreticulin promotes immunity and type I interferon-dependent survival in mice with acute myeloid leukemia

OncoImmunology

Volumn 6, Issue 4, 2017, Pages

  Chen, Xiufen ^a   Fosco, Dominick ^a   Kline, Douglas E ^a   Kline, Justin ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Acute myeloid leukemia; calreticulin; immunity; type I interferon

Indexed keywords

B7 ANTIGEN; CALRETICULIN; CD11 ANTIGEN; CD8 ANTIGEN; CD86 ANTIGEN; COMPLEMENT COMPONENT C5A RECEPTOR; GAMMA INTERFERON; INTERFERON;

ACUTE MYELOID LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER EPIDEMIOLOGY; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CELL MATURATION; CELL PROLIFERATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CROSS PRESENTATION; CYTOLYSIS ASSAY; DENDRITIC CELL; ENZYME LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; IMMUNE RESPONSE; IRRADIATION; MOUSE; MTS ASSAY; NONHUMAN; PHAGOCYTOSIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; T LYMPHOCYTE; TUMOR GROWTH; TUMOR IMMUNITY;

EID: 85016577190     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2016.1278332     Document Type: Article

References (26)

1. Obeid M, Panaretakis T, Joza N, Tufi R, Tesniere A, van Endert P, Zitvogel L, Kroemer G. Calreticulin exposure is required for the immunogenicity of gamma-irradiation and UVC light-induced apoptosis. Cell Death Differ 2007; 14:1848-50; PMID:17657249; http://dx.doi.org/10.1038/sj.cdd.4402201
2. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, Castedo M, Mignot G, Panaretakis T, Casares N, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007; 13:54-61; PMID:17187072; http://dx.doi.org/10.1038/nm1523
3. Zitvogel L, Kepp O, Senovilla L, Menger L, Chaput N, Kroemer G. Immunogenic tumor cell death for optimal anticancer therapy:the calreticulin exposure pathway. Clin Cancer Res 2010; 16:3100-4; PMID:20421432; http://dx.doi.org/10.1158/1078-0432.CCR-09-2891
4. Gao B, Adhikari R, Howarth M, Nakamura K, Gold MC, Hill AB, Knee R, Michalak M, Elliott T. Assembly and antigen-presenting function of MHC class I molecules in cells lacking the ER chaperone calreticulin. Immunity 2002; 16:99-109; PMID:11825569; http://dx.doi.org/10.1016/S1074-7613(01)00260-6
5. Gardai SJ, McPhillips KA, Frasch SC, Janssen WJ, Starefeldt A, Murphy-Ullrich JE, Bratton DL, Oldenborg PA, Michalak M, Henson PM. Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte. Cell 2005; 123:321-34; PMID:16239148; http://dx.doi.org/10.1016/j.cell.2005.08.032
6. Orr AW, Pedraza CE, Pallero MA, Elzie CA, Goicoechea S, Strickland DK, Murphy-Ullrich JE. Low density lipoprotein receptor-related protein is a calreticulin coreceptor that signals focal adhesion disassembly. J Cell Biol 2003; 161:1179-89; PMID:12821648; http://dx.doi.org/10.1083/jcb.200302069
7. Chao MP, Jaiswal S, Weissman-Tsukamoto R, Alizadeh AA, Gentles AJ, Volkmer J, Volkmer J, Weiskopf K, Willingham SB, Raveh T, et al. Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47. Sci Transl Med 2010; 2:63ra94; http://dx.doi.org/10.1126/scitranslmed.3001375
8. Bonifaz LC, Bonnyay DP, Charalambous A, Darguste DI, Fujii S, Soares H, Brimnes MK, Moltedo B, Moran TM, Steinman RM. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J Exp Med 2004; 199:815-24; PMID:15024047; http://dx.doi.org/10.1084/jem.20032220
9. Pawaria S, Binder RJ. CD91-dependent programming of T-helper cell responses following heat shock protein immunization. Nat Commun 2011; 2:521; PMID:22045000; http://dx.doi.org/10.1038/ncomms1524
10. Stoll G, Iribarren K, Michels J, Leary A, Zitvogel L, Cremer I, Kroemer G. Calreticulin expression:interaction with the immune infiltrate and impact on survival in patients with ovarian and non-small cell lung cancer. Oncoimmunology 2016; 5:e1177692; PMID:27622029; http://dx.doi.org/10.1080/2162402X.2016.1177692
11. Fucikova J, Becht E, Iribarren K, Goc J, Remark R, Damotte D, Alifano M, Devi P, Biton J, Germain C, et al. Calreticulin expression in human non-small cell lung cancers correlates with increased accumulation of antitumor immune cells and favorable prognosis. Cancer Res 2016; 76:1746-56; PMID:26842877; http://dx.doi.org/10.1158/0008-5472.CAN-15-1142
12. Matsukuma S, Yoshimura K, Ueno T, Oga A, Inoue M, Watanabe Y, Kuramasu A, Fuse M, Tsunedomi R, Nagaoka S, et al. Calreticulin is highly expressed in pancreatic cancer stem-like cells. Cancer Sci 2016; 107:1599-609; PMID:27561105; http://dx.doi.org/10.1111/cas.13061
13. Wemeau M, Kepp O, Tesniere A, Panaretakis T, Flament C, De Botton S, Zitvogel L, Kroemer G, Chaput N. Calreticulin exposure on malignant blasts predicts a cellular anticancer immune response in patients with acute myeloid leukemia. Cell Death Dis 2010; 1:e104; PMID:21368877; http://dx.doi.org/10.1038/cddis.2010.82
14. Fucikova J, Truxova I, Hensler M, Becht E, Kasikova L, Moserova I, et al. Calreticulin exposure by malignant blasts correlates with robust anticancer immunity and improved clinical outcome in AML patients. Blood 2016; 128:3113-24; PMID:27802968; http://dx.doi.org/10.1182/blood-2016-08-731737
15. Curran E, Chen X, Corrales L, Kline DE, Dubensky TW, Jr., Duttagupta P, Kortylewski M, Kline J. STING pathway activation stimulates potent immunity against acute myeloid leukemia. Cell Rep 2016; 15:2357-66; PMID:27264175; http://dx.doi.org/10.1016/j.celrep.2016.05.023
16. Zhang L, Chen X, Liu X, Kline DE, Teague RM, Gajewski TF, Kline J. CD40 ligation reverses T cell tolerance in acute myeloid leukemia. J Clin Invest 2013; 123:1999-2010; PMID:23619361; http://dx.doi.org/10.1172/JCI63980
17. Low MG, Saltiel AR. Structural and functional roles of glycosyl-phosphatidylinositol in membranes. Science 1988; 239:268-75; PMID:3276003; http://dx.doi.org/10.1126/science.3276003
18. Hildner K, Edelson BT, Purtha WE, Diamond M, Matsushita H, Kohyama M, Calderon B, Schraml BU, Unanue ER, Diamond MS, et al. Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity. Science 2008; 322:1097-100; PMID:19008445; http://dx.doi.org/10.1126/science.1164206
19. Fuertes MB, Kacha AK, Kline J, Woo SR, Kranz DM, Murphy KM, Gajewski TF. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells. J Exp Med 2011; 208:2005-16; PMID:21930765; http://dx.doi.org/10.1084/jem.20101159
20. Diamond MS, Kinder M, Matsushita H, Mashayekhi M, Dunn GP, Archambault JM, Lee H, Arthur CD, White JM, Kalinke U, et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med 2011; 208:1989-2003; PMID:21930769; http://dx.doi.org/10.1084/jem.20101158
21. Woo SR, Fuertes MB, Corrales L, Spranger S, Furdyna MJ, Leung MY, Duggan R, Wang Y, Barber GN, Fitzgerald KA, et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity 2014; 41:830-42; PMID:25517615; http://dx.doi.org/10.1016/j.immuni.2014.10.017
22. Senovilla L, Vitale I, Martins I, Tailler M, Pailleret C, Michaud M, Galluzzi L, Adjemian S, Kepp O, Niso-Santano M, et al. An immunosurveillance mechanism controls cancer cell ploidy. Science 2012; 337:1678-84; PMID:23019653; http://dx.doi.org/10.1126/science.1224922
23. Musahl AS, Huang X, Rusakiewicz S, Ntini E, Marsico A, Kroemer G, Kepp O, Ørom UA. A long non-coding RNA links calreticulin-mediated immunogenic cell removal to RB1 transcription. Oncogene 2015; 34:5046-54; PMID:25579178; http://dx.doi.org/10.1038/onc.2014.424
24. Corrales L, Glickman LH, McWhirter SM, Kanne DB, Sivick KE, Katibah GE, Woo SR, Lemmens E, Banda T, Leong JJ, et al. Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity. Cell Rep 2015; 11:1018-30; PMID:25959818; http://dx.doi.org/10.1016/j.celrep.2015.04.031
25. Goldie H, Butler CH, Anderson MM, Maxwell MC, Hahn PF. Growth characteristics of free C1498 granulocytic leukemia tumor cells in the peritoneal fluid and the blood of C57 mice. Cancer Res 1953; 13:125-9; PMID:13042796
26. Zhang L, Gajewski TF, Kline J. PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model. Blood 2009; 114:1545-52; PMID:19417208; http://dx.doi.org/10.1182/blood-2009-03-206672